透景生命(300642) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥125,172,199.85, a decrease of 36.73% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥8,052,983.97, down 82.06% year-on-year[3]. - The basic earnings per share (EPS) was ¥0.0493, reflecting an 82.10% decline compared to the previous year[3]. - Total operating revenue for Q3 2023 was CNY 401,182,559.69, a decrease of 22.6% compared to CNY 518,469,451.66 in the same period last year[23]. - Operating profit for Q3 2023 was CNY 41,492,254.54, a decline of 56.1% from CNY 94,452,589.88 in Q3 2022[23]. - Net profit for Q3 2023 was CNY 41,048,518.15, down 56.5% compared to CNY 94,252,835.68 in the previous year[23]. - The company’s total comprehensive income for Q3 2023 was CNY 40,001,344.94, down 54.4% from CNY 87,702,033.20 in Q3 2022[25]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥1,658,307,905.32, a decrease of 0.39% from the end of the previous year[3]. - Total assets as of September 30, 2023, were CNY 1,658,307,905.32, slightly down from CNY 1,664,722,687.00 at the beginning of the year[22]. - Total liabilities decreased to CNY 149,214,361.14 from CNY 184,073,131.32, a reduction of 19.0%[21]. - The company’s equity attributable to shareholders increased to CNY 1,499,249,981.44 from CNY 1,472,395,408.01, reflecting a growth of 1.8%[22]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥114,284,975.31, down 12.45% compared to the same period last year[10]. - The net cash flow from operating activities was CNY 114,284,975.31, a decrease of 12.4% compared to CNY 130,540,188.44 in the same period last year[27]. - Cash and cash equivalents increased to CNY 396,712,236.53 as of September 30, 2023, from CNY 243,484,642.21 at the beginning of the year, representing a growth of 62.9%[20]. - Cash and cash equivalents at the end of the period increased to CNY 396,712,236.53, up 47.8% from CNY 268,426,629.11 at the end of Q3 2022[28]. - The company reported a net cash flow from investment activities of CNY 64,030,412.52, compared to a negative cash flow of CNY -5,030,771.05 in the previous year[27]. - The total cash inflow from financing activities was CNY 22,451,500.00, an increase from CNY 12,582,609.34 in the previous year[27]. - The company’s cash outflow from financing activities was CNY 47,134,621.29, a decrease of 24.7% compared to CNY 62,686,833.23 in the previous year[27]. Operational Metrics - The company experienced a 35.94% reduction in operating costs, totaling ¥147,321,873.47, primarily due to decreased sales revenue[9]. - Total operating costs for Q3 2023 were CNY 373,678,948.58, down 16.0% from CNY 444,813,936.71 in Q3 2022[23]. - The gross margin for the third quarter of 2023 increased to 69.26%, compared to 62.12% in the same period last year[16]. - The overall gross margin for the first nine months of 2023 improved to 63.28%, up from 55.64% in the same period last year[16]. - The proportion of self-produced reagents in total revenue increased from 68.39% in the same period last year to 87.89%[16]. Investments and Shareholder Information - The company has invested 43.17 million RMB to acquire land use rights for the construction of its headquarters and industrial base in Shanghai[16]. - The company plans to acquire minority shareholder equity in its controlling subsidiary for a total of 861,520 RMB[17]. - The top shareholder, Yao Jian'er, holds 19.95% of the shares, amounting to 32,753,700 shares, with 3,556,000 shares pledged[11]. - The second-largest shareholder, Lingfei Group Co., Ltd., holds 7.33% of the shares, totaling 12,035,800 shares, with 8,580,000 shares pledged[11]. - The company holds a 3.46% stake in its subsidiary, Shanghai Maishi Biotechnology Co., Ltd., to enhance management and control capabilities[18]. Other Financial Metrics - The company reported a significant increase in other receivables, which rose by 286.71% to ¥6,356,131.07 due to increased land deposit payments[7]. - The company’s research and development expenses for Q3 2023 were CNY 57,748,024.31, up from CNY 53,510,582.27 in Q3 2022, indicating a year-over-year increase of 8.4%[23]. - Government subsidies recognized increased by 83.68% to ¥8,081,324.77 compared to the previous year[9]. - The company reported a 100% decrease in prepayments, with a balance of ¥0.00, as sales related to prepayments were realized during the period[8].